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A B S T R A C T
Aims: This preliminary randomized, parallel-group comparative study evaluated the eﬃcacy of ipragliﬂozin
for reduction of small dense low-density lipoprotein cholesterol (sd LDL-C) levels in Japanese patients
with type 2 diabetes mellitus (T2DM).
Methods: Sixty-two patients with T2DM (age, 56 ± 8 years; hemoglobin A1c levels, 8.1 ± 0.9%; BMI,
27.5 ± 3.3 kg/m2) were randomly assigned in a 2:1 ratio to receive ipragliﬂozin (50 mg/day) (treatment
group; n = 40) or continued treatment (control group; n = 22) for 12 weeks.
The primary endpoints were changes in sd LDL-C levels detected using the LipoPhor AS® system; the
secondary endpoints included changes in the sd LDL-C/large buoyant LDL-C (lb LDL-C) ratio, a surrogate
marker for LDL particle size, and percent changes in routine lipid parameters.
Results: The treatment group exhibited a statistically signiﬁcant reduction from baseline for LDL-C levels
(−0.37 mg/dL vs. 14.4 mg/dL, p = 0.038), sd LDL-C levels (−1.28 mg/dL vs. 2.81 mg/dL, p = 0.012), and sd
LDL-C/lb LDL-C ratio (−3.20% vs. 4.58%, p = 0.040) compared with the control group. Multiple regression
analysis among all subjects revealed change in TG levels (p = 0.011) and LDL-C levels (p = 0.024) as well
as change in body weight (p = 0.006) as independent factors contributing to the reduction in sd LDL-C.
Conclusions: Ipragliﬂozin may have a potential for lowering sd LDL-C levels associated with increasing
LDL particle size in Japanese patients with T2DM.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Type 2 diabetes mellitus (T2DM) is associated with a substan-
tially increased cardiovascular (CV) risk [1], and several international
guidelines statements addressing T2DMmanagement [2,3] under-
score the need to prevent and reduce CV complications.
In light of the multi-faceted pathogenesis of CV disease in dia-
betes, it would be advantageous for a speciﬁc pharmaceutical
intervention to attenuate atherosclerosis risk multi-dimensionally
and beyond glycemic control alone [4]. The potential effect of such
interventions on CV riskmight ultimately depend on the drug’s mode
of action in terms of the CV pathway being modulated. However,
to date, the potential effects of speciﬁc glucose-lowering agents –
that is, sulphonylurea (SU), glinides, metformin, thiazolidinediones,
insulin, glucagon-like peptide-1 receptor analogs, or dipeptidyl-
peptidase-4 (DPP-4) inhibitors – on CV events in patients with T2DM
remain uncertain [5], although some agents, such as metformin and
pioglitazone, have been reported to reduce major cardiovascular
events in a limited number of newly diagnosed low-risk obese pa-
tients (n = 342) with T2DM [6] or to reduce the risk with marginal
signiﬁcance (p = 0.027) in high-risk patients with T2DM [7],
respectively.
Sodium glucose cotransporter-2 (SGLT-2) inhibitors are a new
class of glucose-lowering agents that reduce hyperglycemia in pa-
tients with T2DM by limiting renal glucose reabsorption; as a result,
they increase urinary glucose excretion (UGE) [8]. Since SGLT-2 in-
hibitors’ mode of action is independent of insulin secretion, these
agents are associated with a low risk of hypoglycemia, which has
been linked to increased CV events [9]. In addition, they have been
demonstrated to correct post-prandial glucose level [10], improve
insulin sensitivity [11], reduce systolic and diastolic blood pres-
sure without a compensatory increase in heart rate [12], decrease
body weight mainly due to reduction in visceral or subcutaneous
fat mass [8], and reduce urinary albumin excretion [13] and serum
level of uric acid [14], all of which are potential or established CV
risk factors. In the recent EMPA-REG outcomes trial, empagliﬂozin,
an SGLT-2 inhibitor, reduced the rates of death from cardiovascu-
lar causes, hospitalization for heart failure, and death from any cause
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by more than 30% in patients with T2DM at a high risk of cardio-
vascular disease during 3.1 years [15]. However, the preventive
mechanisms are not yet known.
In this context, regarding dyslipidemia, which are well-known
established CV risk factors, SGLT-2 inhibitors are associated with a
small increase in HDL-C as well as an increase in LDL-C with con-
comitant reductions in triglyceride (TG) levels [16,17].Whether these
small lipid changes are clinically relevant and whether they could
potentially affect total CV risk requires further clariﬁcation.
Although statin therapy targeting a reduction in LDL-C de-
creases the risk of coronary heart disease (CHD) and all-cause
mortality, a substantial number of cases of CHD are not prevented
and residual risk factors remain unclear, stimulating the search for
a secondary treatment target [18].
Compared with large buoyant LDL (lb LDL), small dense LDL (sd
LDL) are thought to be more atherogenic as a result of their better
penetration of the arterial wall, lower binding aﬃnity for the LDL
receptor, longer plasma half-life, and weaker resistance to oxida-
tive stress [19]. Several studies have reported a two- to three-fold
increase in CHD risk in patients with sd LDL [20]. In particular, sd
LDL is reportedly predominant in patients with T2DM [21], a well-
known independent risk factor for coronary artery disease [22].
Ipragliﬂozin (ASP1941; Astellas Pharma Inc. Tokyo, Japan and
Kotobuki Pharmaceutical Co., Ltd, Nagano, Japan) is a novel and se-
lective SGLT2 inhibitor and is one of the ﬁrst published C-aryl
glycoside compounds (as opposed to the labile ortho-attachment
of O-glycoside molecules seen in in vivo conditions) [23]. In a re-
cently implemented, randomized, double-blind, placebo-controlled
study using 129 Japanese patients with T2DM, 50 mg ipragliﬂozin
once daily has been associated with a signiﬁcant elevation in HDL-C
levels (+2.7 mg/dL) with a concomitant small non-signiﬁcant de-
crease in TG levels (−12.3 mg/dL) as well as no increase in LDL-C
levels (−1.4 mg/dL) [24].
Here, we conducted a preliminary open-label, randomized,
parallel-group comparative study evaluating the eﬃcacy of 50 mg
ipragliﬂozin once daily for reduction of sd LDL-C levels and
subfraction distribution as evaluated using the LipoPhor AS® system
in Japanese patients with T2DM.
Subjects, materials and methods
Ethics statement
This study was conducted in accordance with Good Clinical Prac-
tice, International Conference on Harmonization guidelines, and
applicable laws and regulations. The study protocol was approved
by the ethics committee of Fukui-ken Saiseikai Hospital. After re-
ceiving a full explanation of the study, all patients provided written
informed consent before enrollment.
Study population
Eligible patients were aged 20–65 years, had been diagnosedwith
T2DM for at least 12 weeks, had baseline body mass indices (BMIs)
of 24.0–40.0 kg/m2, and had HbA1c levels of 7.0–10.0% (7.5–10.0%
when the patient has regularly taken an SU or glinides). Patients
were instructed to continue with their recommended diets and ex-
ercise habits. We excluded patients with type 1 diabetes, insulin use,
fasting triglyceride levels ≥4.5 mmol/L (400 mg/dL), an estimated
glomerular ﬁltration rate (eGFR) of less than 60 mL/min/1.73 m2,
dysuria caused by a neurogenic bladder or benign prostatic hyper-
trophy, repeated urinary tract infections (UTIs) or a UTI at screening,
diﬃculty reaching suﬃcient water intake due to an attenuated sense
of thirst, chronic disease requiring continuous use of steroids
or immunosuppressants, and past history of cardiac events
(e.g., angina pectoris, nonfatal myocardial infarction, and coro-
nary revascularization as adjudicated hospitalized cardiovascular
events). Additionally, subjects with malignant tumors, unstable psy-
chiatric disorders, severe trauma, and/or infection as well as those
who were pregnant or breast-feeding were also excluded as
were those who were considered unlikely to comply with study
requirements.
At the time of enrollment and 12 weeks after, patients’ base-
line characteristics and clinical data, including a routine lipid proﬁle
and the LipoPhor AS® system, were investigated.
Sixty-two eligible patients were randomly assigned in a 2:1 ratio
using the EDC system to receive either 50mg ipragliﬂozin once daily
(treatment group; n = 40) or continued treatment (control group;
n = 22) for 12 weeks.
The primary endpoints were changes in sd LDL-C levels and sd
LDL-C/total LDL-C ratios from baseline between the two treat-
ment groups. The secondary endpoints were changes in mid-band
LDL-C levels, mid-band LDL-C/total LDL-C ratio, sd LDL-C/lb LDL-C
ratio, and the percent change of routine lipid parameters (LDL-C,
total cholesterol, high-density lipoprotein cholesterol [HDL-C], tri-
glycerides [TG], non HDL-cholesterol) from baseline between the
groups. Other secondary endpoints included changes in HbA1c,
glycated albumin levels, and body weight from baseline between
the groups. Levels of lb LDL-C were calculated by subtracting sd
LDL-C andmid-band LDL-C levels from total LDL-C. Levels of lb LDL-C
estimated using this method were reported to be well correlated
with the values determined by ultracentrifugation (r = 0.858,
p < 0.0001) [25]. The sd LDL-C/lb LDL-C was calculated as a surro-
gate marker for LDL particle size [26]. To assess safety, the incidence
and details of adverse events and laboratory abnormalities were
investigated.
Compliance with treatment was assessed at 4, 8, and 12 weeks
by interview. In principal, any change of the dosage regimen of con-
comitant anti-diabetes and antilipidemic drugswas prohibited during
the study. Laboratory tests (including biochemistry tests, hematol-
ogy tests, urinalysis, serum lipids, and other parameters) were
performed after an overnight fast at randomization and 12 weeks
after randomization when LDL-C subfractions were re-evaluated
using the LipoPhor AS® system. All blood tests were performed using
standard methods. LDL-C level was calculated using the Friedewald
equation [27]. Non-high-density lipoprotein cholesterol (non-HDL-
C) levels were calculated by subtracting the HDL-C level from the
total cholesterol level. Body mass index (BMI) was calculated as
weight (kg) divided by height squared (m2). eGFR was calculated
using the formula reported by Matsuo et al. [28]. Presence of dia-
betic retinopathy was evaluated by fundus examination performed
by an ophthalmologist. Hypertension was deﬁned as systolic blood
pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg or
current use of antihypertensive agents.
This study is registered with the University Hospital Medical In-
formation Network Clinical Trials Registry (UMIN-CTR; Japan),
number UMIN000014422.
Polyacrylamide-gel disc electrophoresis (PAGE) and
densitometric analysis
PAGEwas performed using a commercial kit (LipoPhor AS®; ASKA
Co., Ltd., Kanagawa, Japan) [29]. Brieﬂy, serum samples (25 μL) were
added to 200 μL of the loading gel solution containing Sudan
Black B and injected into a 3% polyacrylamide gel. The gel was
photopolymerized for 30 min, and the loaded samples were elec-
trophoresed for 25min. The resulting electrophoresed patterns were
scannedwith a densitometer (Densitron Finger Printer; Jokoh, Japan),
and the percentages of the area under the curve (AUC%) for the
VLDL, LDL, and HDL peaks were calculated. The AUC% values of
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mid-band LDL and sd LDL were identiﬁed according to a report by
Mishima and colleagues [30,31] with slight modiﬁcations. First, the
peak positions of VLDL and HDL were set as 0 and 1 (relative mi-
gration [Rm]), as shown in Fig. 1. Second, the scanned spectrumwas
overlaid with a control spectrum representing normal lipoprotein
levels (Fig. 1). Finally, the presence or absence of sd LDL and mid-
band LDL was determined by identifying the excess area in the
spectrum of samples on either or both sides of the control LDL peak.
If there were substantial areas for mid-band LDL and/or sd LDL, we
used the AUC% of Rm > 0.40 and Rm 0.10–0.18 in the LDL peak as
sd LDL and mid-band LDL, respectively. The LDL-C value calcu-
lated from the Friedewald equation multiplied by the respective
AUC% was used as the calculated value of each LDL-C subfraction.
The ratios (%) of sd LDL-C and mid-band LDL-C to total LDL-C were
also determined.
Statistical analysis
Data are expressed as means ± standard deviation unless oth-
erwise noted. Comparisons of discrete variable data were analyzed
using the chi-squared test or Fisher’s direct test, as appropriate. Dif-
ferences between two variables were examined for statistical
signiﬁcance using the two-tailed Student’s paired or unpaired t-test,
as appropriate. Correlations between sets of two independent con-
tinuous variables were investigated using Spearman’s rank
correlation coeﬃcient method. Two-way repeatedmeasures ANOVA
with post-hoc Bonferroni tests were used to determine differ-
ences in parameter changes over the time.
Multiple linear regression analysis among all study subjects
(n = 62) was conducted to determine the independent predictors
of changes in sd LDL-C levels (Δsd LDL-C) and the sd LDL-C/lb LDL-C
ratio (Δsd LDL-C/lb LDL-C ratio). All variables considered clinically
meaningful parameters for a patient’s background were employed
as independent variables inmultivariate analysis (i.e., sex, age, change
in BMI, diabetes duration, change in LDL-C, change in TG, and change
in HbA1c). Δsd LDL-C, Δsd LDL-C/lb LDL-C ratio, change in BMI, LDL-
C, TG, and HbA1c were all calculated as each level 12 weeks after
starting ipragliﬂozin minus the baseline levels. For all tests, p < 0.05
was considered statistically signiﬁcant. All the statistical analyses
were performed using the JMP version 5.1 software (SAS Institute
Inc., Cary, NC, USA).
Results
Subject characteristics and lipids at baseline
The mean ± standard deviation for age, BMI, HbA1c, and glycated
albumin levels at baseline for all study subjects (n = 62) were
55.6 ± 7.7 years, 27.6 ± 3.3 kg/m2, 8.1 ± 1.0%, and 19.5 ± 3.2%,
respectively. The relative percentages of users of concomitant
antihyperglycemic agents (sulphonylurea: metformin: DPP-4 in-
hibitors) and antihyperlipidemic agents (statin: ﬁbrates: ezetimibe)
at baseline among all study subjects were 56:82:74 and 79:7:5, re-
spectively. The baseline clinical characteristics of subjects in the two
groups (treatment group: n = 40; control group: n = 22) are pre-
sented in Table 1. The two groups were well matched according to
gender, age, BMI, eGFR, ratio of statin use, and diabetes character-
istics, including duration, baseline HbA1c, oral antihyperglycemic
therapy, and complications as well as baseline lipid levels, includ-
ing levels of total cholesterol, LDL-C, TG, sd LDL-C, mid-band LDL-
C, and sd LDL-C/lb LDL-C ratio.
All patients completed the study protocol without any with-
drawals due to treatment-related serious adverse events. Mean
compliance was found to be ≥95% during the study period.
Changes in routine lipids parameters
There were no signiﬁcant differences in the changes from base-
line between the treatment and control groups for TG levels
(133 ± 72→121 ± 60 mg/dL vs. 154 ± 71→157 ± 85 mg/dL, p = 0.42,
respectively) and HDL-C levels (48 ± 9→50 ± 10 mg/dL vs.
45 ± 10→48 ± 10mg/dL, p = 0.72). However, the treatment group ex-
hibited a statistically signiﬁcant decrease compared with the control
group with respect to changes in total cholesterol levels
(169 ± 38→165 ± 35mg/dL vs. 171 ± 33→184 ± 36mg/dL, p = 0.010),
LDL-C levels (95 ± 31→91 ± 26 mg/dL vs. 95 ± 28→105 ± 30 mg/dL,
p = 0.020), and non-HDL-C levels (122 ± 34→115 ± 30 mg/dL vs.
126 ± 31→136 ± 33 mg/dL, p = 0.010).
Similarly, there were no signiﬁcant differences in changes from
baseline between the treatment and control groups for the percent
changes in TG levels (+2.2% vs. +11.7%, p = 0.50, respectively) and
HDL-C levels (+6.2% vs. +8.2%, p = 0.60). However, the treatment group
exhibited a statistically signiﬁcant decrease compared with the
control group with respect to the percent changes in total choles-
terol levels (−1.3% vs. +9.2%, p = 0.011) and non-HDL-C levels (−3.5%
vs. +10.8%, p = 0.012).
Changes in LDL-C and its subfractions (Fig. 2)
There were no signiﬁcant differences in the changes from base-
line between the treatment and control groups for mid-band LDL-C
(+0.1mg/dL vs. +1.94mg/dL, p = 0.29) and lb LDL-C levels (−3.43mg/
dL vs. +4.91 mg/dL, p = 0.127). However, the treatment group
exhibited a statistically signiﬁcant reduction from baseline com-
pared with the control group for LDL-C levels (−4.27 mg/dL vs.
Figure 1. An example of the lipoprotein densitometric patterns obtained by PAGE
analysis. The solid line shows the reference densitometric pattern. The sample den-
sitometric pattern of a patient (yellow ﬁlled areas) was overlaid with the reference
pattern. The pattern was separated into 3 fractions: very low-density lipoprotein
(VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). The area
between Rm 0.10 and Rm 0.18 was assigned as mid-band LDL. In addition, the excess
area on the right side of the LDL peak (Rm > 0.40) was assigned as small-dense LDL.
(For interpretation of the references to color in this ﬁgure legend, the reader is re-
ferred to the web version of this article.)
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+9.71 mg/dL, p = 0.020) and sd LDL-C levels (−1.28 mg/dL vs.
+2.81 mg/dL, p = 0.012).
In addition, the treatment group exhibited a statistically signif-
icant reduction from baseline compared with the control group for
the percent changes of LDL-C levels (−0.37% vs. +13.1%, p = 0.049),
mid-band LDL-C levels (+0.05% vs. +1.91%, p = 0.025), sd LDL-C levels
(−0.74% vs. +1.10%, p = 0.038), and sd LDL-C/lb LDL-C levels (−3.20%
vs. +4.58%, p = 0.040).
A Spearman’s rank correlation analysis revealed a strong posi-
tive correlation between Δsd LDL and the Δsd LDL-C/lb LDL-C ratio
among all study subjects (p < 0.0001), indicating that a reduction
in sd LDL-C levels might be potently linked to an increase in LDL
particle size.
Multiple linear regression analysis
The results of multiple linear regression analysis among all study
subjects indicate that the factors contributing signiﬁcantly to Δsd
LDL-C were change in body weight (p = 0.006, r2 = 0.183), change in
TG (p = 0.011, r2 = 0.069), and change in LDL-C (p = 0.024, r2 = 0.076)
(Table 2A). Sex, age, diabetes duration, and change in HbA1c were
not signiﬁcant predictors. Change in body weight, change in LDL-
C, and change in TG together accounted for 32.8% of the total variance
in Δsd LDL-C (Table 2A).
The results of the same analysis indicate that the factors con-
tributing signiﬁcantly to Δsd LDL-C/lb LDL-C ratio were change in
TG (p = 0.002, r2 = 0.213) and change in body weight (p = 0.022,
r2 = 0.102) (Table 2B). Sex, age, diabetes duration, change in HbA1c,
and changes in LDL-Cwere not signiﬁcant predictors. Change in body
weight and change in TG together accounted for 31.5% of the total
variance in the Δsd LDL-C/lb LDL-C ratio (Table 2B).
Changes in hemoglobin A1c, glycated albumin levels,
and body weight
The treatment group exhibited a statistically signiﬁcant de-
crease in hemoglobin A1c and glycated albumin levels compared
with the control group 12 weeks after starting 50 mg ipragliﬂozin
once daily (−0.61 ± 0.52% vs. +0.52 ± 0.74%, p < 0.0001 and
−2.92 ± 2.48% vs. +0.89 ± 2.45%, p < 0.0001, respectively). The treat-
ment group similarly exhibited a statistically signiﬁcant decrease
in body weight compared with the control group (−1.51 ± 1.28 kg
vs. +0.45 ± 0.77 kg, p < 0.0001). Therefore, these glycemic and weight
changes in response to the study drug are confounding factors in
our study results. Changes in various clinical parameters other than
Table 1
Baseline clinical characteristics of the study subjects with type 2 diabetes mellitus between the treatment and control groups
Characteristic Treatment
group
Control
group
P value
n 40 22 ns
Gender (male/female) 26/14 14/8 ns
Age (years) 54.8 ± 9.3 55.4 ± 7.5 ns
BMI (kg/m2) 27.8 ± 3.9 27.3 ± 3.1 ns
Diabetes duration (years) 9.7 ± 4.6 9.5 ± 4.4 ns
HbA1c (%) 8.1 ± 1.0 8.2 ± 1.1 ns
Concomitant antihyperglycemic agents SU/Met/DPP-4i) (%) 55/83/80 59/82/73 ns
Concomitant antihyperlipidemic agents (statin/ﬁbrates/ezetimibe) (%) 80/8/5 77/5/5 ns
Total cholesterol (mg/dL) 169 ± 38 171 ± 33 ns
LDL-cholesterol (mg/dL) 95 ± 31 92 ± 26 ns
Triglycerides (mg/dL) 133 ± 72 154 ± 71 ns
HDL-cholesterol (mg/dL) 48 ± 9 45 ± 10 ns
Non HDL-cholesterol (mg/dL) 122 ± 34 126 ± 31 ns
Small-dense LDL-cholesterol (mg/dL) 2.9 ± 4.9 2.9 ± 4.4 ns
Large-buoyant LDL-cholesterol (mg/dL) 82.0 ± 28 82.5 ± 26 ns
Mid-band LDL-cholesterol (mg/dL) 10.1 ± 6.0 10.0 ± 5.6 ns
Small-dense LDL-cholesterol/LDL-cholesterol ratio (%) 1.8 ± 3.7 1.5 ± 2.0 ns
Mid-band LDL-cholesterol/LDL-cholesterol ratio (%) 6.2 ± 2.5 12.7 ± 6.5 ns
sd LDL-C/lb LDL-C ratio(%) 5.3 ± 16.0 6.1 ± 2.5 ns
eGFR (mL·min−1·1.73m−2) 79.5 ± 14.9 76.1 ± 13.6 ns
Complications
Retinopathy (n) 5 (13%) 1 (5%) ns
Hypertension (n) 21 (53%) 13 (59%) ns
Dyslipidemia (n) 33 (83%) 18 (82%) ns
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; Met, metformin; DPP-4i, DPP-4 inhibitors; LDL, low-density lipo-
protein; HDL, high-density lipoprotein; eGFR, estimated glomerular ﬁltration rate; ns, not signiﬁcant.
All values are means ± standard deviations or numbers of subjects with percentages in parentheses. P values between two groups
of subjects were obtained using the unpaired t-test, chi-squared test, or Fisher’s direct test, as appropriate.
Figure 2. Mean change from baseline in LDL-C, mid-band LDL-C, lb LDL-C, and sd
LDL-C levels after 12 weeks in both treatment groups. Abbreviations: LDL, low-
density lipoprotein; lb LDL, large buoyant low-density lipoprotein; sd LDL, small dense
low-density lipoprotein. All values are means ± standard errors. White and solid bars
indicate the control group (n = 22) and the treatment group (n = 40), respectively.
p values comparing the two groups of subjects were obtained using an unpaired-t
test. *p = 0.016 versus the control group.
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lipids between the two treatment groups were shown in Table S1
in the Supplementary Appendix.
Discussion
Our present data revealed that administration of 50 mg
ipragliﬂozin once daily provided a statistically signiﬁcant reduc-
tion in the percent LDL-C levels, sd LDL-C levels, and sd LDL-C/lb
LDL-C ratio compared with that in the control group. These results
indicate that this compound may lower sd LDL-C levels associated
with increasing LDL particle size. To the best of our knowledge, this
is the ﬁrst randomized control study to investigate the sd LDL-C-
lowering effect of SGLT-2 inhibitors.
The predominance of sd LDL particles, which leads to the de-
crease of LDL particle size, has been reported to be associated with
enhanced cardiovascular risk [32,33]; accordingly, sd LDL blood con-
centration is signiﬁcantly higher in patients with T2DM or coronary
artery disease than in healthy individuals [34]. Thus, the increase
of LDL particle size accompanied by the decrease of sd LDL might
represent a novel preventive therapeutic target beyond lipid-
lowering itself, especially in patients with T2DM.
However, the LDL subfractionation methodology is an impor-
tant issue, because there is substantial heterogeneity among the
methodologies currently used to analyze LDL subfractions [35]. In
fact, no method is regarded as the golden standard for LDL
subfraction analysis or for estimation of LDL particle size [35]. In
the present study, we used the LipoPhor AS® System to analyze LDL
subfractions. This system provides a rapid LDL subclass analysis using
high-resolution 3% polyacrylamide gel tubes, determines the amount
of cholesterol contained in each of these fractions, and ﬂags results
that exceed the “normal” reference range. This method has been
validated as an accurate, inexpensive, and easy-to-use technique for
visualizing lipoprotein fractions and subfractions [29]. In this context,
the Lipoprint® LDL system, which employs a measurement princi-
ple similar to the LipoPhor AS® System based on polyacrylamide gel
lipoprotein disc electrophoresis, is the only FDA-approved test for
measuring LDL subfraction cholesterol levels. The calculated values
of sd LDL-AUC% × TC using this system were highly correlated with
values for sd LDL-cholesterol using a homogeneous assay (r = 0.81)
method [29] and were strongly correlated with ultracentrifugation
results for sd LDL (r = 0.95) [36], which is regarded as themost robust
method for measurements of sd LDL-C. Therefore, potential error
is not expected in comparison to other methods, such as the simple
precipitation method, which is also highly correlated with ultra-
centrifugation for sd LDL (r = 0.88) [25]. Further, this PAGE method
can be performed using a commercial kit and does not require ex-
pensive instruments.
SGLT-2 inhibitors can reduce hyperglycemia in patients with
T2DM by an insulin-independent manner, namely, reducing renal
glucose reabsorption. At the same time, this Do¯jiniclass of agents
decreases body weight mainly due to reduction in visceral or sub-
cutaneous fat mass [11], which are the main production sites of free
fatty acid [37,38]. Therefore, under SGLT-2 inhibitor medication, it
is theoretically presumed that the liver may decrease TG produc-
tion by utilizing the plasma glucose and free fatty acid as substrates,
resulting in reduction in serum sd LDL levels through reduced pro-
duction of TG-rich VLDL in the liver.
In this context, the results of our multiple linear regression anal-
ysis among all study subjects, which revealed that the independent
factors contributing to the reduction in sd LDL-C levels and sd LDL-
C/lb LDL-C ratio were mainly change in TG levels as well as changes
in LDL-C levels and body weight, are partially consistent with the
above-mentioned mechanisms for sd LDL-C production, although
we do not have data regarding changes in free fatty acid levels in
this study.
On the other hand, it is unclear whether the small reduction in
sd LDL levels (−1.28mg/dL in the present study) would have an overt
clinical beneﬁt during long-term observation. In addition, there is
no current consensus regarding the target sd LDL levels in pa-
tients with hypercholesterolemia and diabetes. In the SATURN trial,
which used two intensive statin regimens [39], the ﬁnal sd LDL level
was non-signiﬁcantly reduced in the rosuvastatin 40mg daily group
compared to that in the atorvastatin 80 mg daily group (18.3 ± 12.5
vs. 19.1 ± 12.2 mg/dL; MD, −0.80 mg/dL; 95% CI, −2.30 to 0.70 mg/
dL; p = 0.30), and the frequency of the ﬁrst major adverse
cardiovascular event was similar in the two groups (7.5% and 7.1%,
respectively).
Some previous studies have reported that SGLT-2 inhibitors are
associated with a small increase in HDL-C as well as an increase in
LDL-Cwith concomitant reductions in triglyceride (TG) levels [16,17].
In particular, canagliﬂozin is associated with an average 8% in-
crease in plasma levels of LDL-C compared with placebo [40],
mechanisms of which have not been elucidated.
In contrast with these previous studies using other SGLT-2 in-
hibitors, themechanism underlying the signiﬁcant reduction in LDL-C
levels by administration of 50 mg ipragliﬂozin should be eluci-
dated. First, under treatment with an SGLT-2 inhibitor, LDL-C
production is theoretically supposed to decrease through reduced
VLDL production, a precursor of LDL, in the liver. In fact, post-hoc
subgroup analyses using data from a phase III study of canagliﬂozin
in Japanese patients with T2DM [41] showed that the mean LDL-C
level decreased in subgroups with a baseline LDL-C level ≥120 mg/
dL that were treated with canagliﬂozin at doses of 100 mg and
200mg, indicating that this agent did not increase the risk of LDL-C
elevation in the LDL-C ≥120 mg/dL subgroup.
By contrast, it is very diﬃcult to understand the contradictory
effects on LDL-C levels observed in this study with those of other
studies, such as those using canagliﬂozin [17,40], since in all of these
studies, the mean LDL-C levels of subjects were all under 120 mg/
dL. The treatment group in this study had a high frequency of
combination therapy with DPP-4 inhibitors, mainly sitagliptin, com-
pared with the treatment groups of previous studies [17,40] (80%
vs. 0% and 0%, respectively). Amelioration of glucose toxicity via
SGLT2 inhibition might augment the LDL-C-lowering effect of DPP-4
inhibitors associated with a high frequency of statin use in this study
Table 2
Independent predictors of Δsd LDL-C and the Δsd LDL-C/lb LDL-C ratio, and changes
in HbA1c among all study subjects based on multiple linear regression analysis
Variables β coeﬃcient Standard
error
t value p value
(A)
Intercept 1.742 6.321 0.276 0.786
Change in BW (kg) 1.546 0.540 2.865 0.006
Change in TG (mg/dL) 0.027 0.010 2.648 0.011
Change in LDL-C (mg/dL) 0.085 0.037 2.324 0.024
Change in HbA1c (%) 0.0663 1.116 0.594 0.555
Multiple R-squared (r2) 0.328
(B)
Intercept 12.90 14.80 0.871 0.388
Change in TG (mg/dL) 0.084 0.024 3.492 0.001
Change in BW (kg) 2.902 1.263 2.297 0.026
Change in HbA1c (%) −0.331 2.613 −0.127 0.900
Multiple R-squared (r2) 0.324
(A) Dependent variable: Δsd LDL-C (mg/dL).
(B) Dependent variable: Δsd LDL-C/lb LDL-C ratio (%). Independent variables: sex,
age, change in BW, diabetes duration (years), changes in LDL-C, changes in TG, and
change in HbA1c (%). Sex: female = 0, male = 1.
Sex, age, diabetes duration, and change in HbA1c within the model A, and sex, age,
diabetes duration, change in HbA1c and in LDL-C within the model B were not re-
tained, because they were not signiﬁcant predictors.
BW: body weight, LDL-C: LDL-cholesterol, TG: triglyceride, HbA1c: hemoglobin A1c.
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(79%) [42]. In addition, the observed effects might be explained based
on differences in race, or the type of SGLT2 inhibitor itself. Indeed,
previous studies using ipragliﬂozin [43], in whichmean LDL-C levels
of the treatment group were 108 mg/dL, showed no signiﬁcant el-
evation in LDL-C levels compared with those in the placebo group
at 24 weeks after the treatment (p = 0.933).
The present study had several limitations. First, enrolled sub-
jects constitute a relatively small number. However, baseline
characteristics, such as sex, age, diabetes characteristics, and lipid
proﬁles, did not differ between the two treatment groups, and none
of the 62 randomized patients withdrew from the study. Second,
the relatively short study duration of 12 weeks may be a limita-
tion. Third, the LDL-C levels of this study population were already
generally well controlled (93.8 mg/dL) under a high frequency of
statin use (79%), which could confound the results. However, the
control and treatment group showed similar frequencies of statin
use (77% vs. 80%) and the relative percentages of atorvastatin and
rosuvastatin use [44] (82:18 vs. 84:16, respectively). Furthermore,
additional multiple linear regression analysis among all subjects in-
cluded in this study showed that statin use did not independently
contribute to Δsd LDL-C (p = 0.55).
Fourth, we cannot exclude the potential glycemic effect of the
study drug on reducing sd LDL-C levels [45], since the control group
was not treated to match the glycemic control level. However, the
change in HbA1c was not an independent predictor of Δsd LDL-C
in the multiple regression analysis of all study subjects, indicating
that HbA1c lowering might not be a main contributor for the ob-
served sd LDL-C lowering in this study.
In conclusion, our present study suggests that 50mg ipragliﬂozin
once daily may reduce sd LDL-C levels and increase LDL particle size,
potentially contributing to long-term CV risk reduction in pa-
tients with T2DM.
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